Hormones were the key in my case to keeping the MS at bay. Pregnancy was helpful, but nursing was dramatically effective.
I remember reading this fact also, but when I researched into it further, I kept coming across articles that said Prolactin caused permeability in the BBB (or something to that effect).DIM wrote:Prolactin have found to be benefficial in MS as all other pregnacy hormones, progesteron and estrogen!
WikiPedia wrote:Prolactin provides the body with sexual gratification after sexual acts: The hormone counteracts the effect of dopamine, which is responsible for sexual arousal. This is thought to cause the sexual refractory period. The amount of prolactin can be an indicator for the amount of sexual satisfaction and relaxation. Unusually high amounts are suspected to be responsible for impotence and loss of libido (see hyperprolactinemia Symptoms). Prolactin also stimulates proliferation of oligodendrocyte precursor cells. These cells differentiate into oligodendrocytes, the cells responsible for the formation of myelin coatings on axons in the central nervous system.
My questions are: with the FDA position on bio identical hormones, is it still possible to get Estriol from a compounding pharmacy. And for those of you who do take it, how long before/if you notice any improvements?
I live in a small community, how do you find someone to prescribe Estriol? Also, her question was how much progesterone should go with it? Is it possible to contact Dr. Voskuhl or some other person leading in the research to get more information to my Doctor?
P20 (on page 47 of the program) HRT Contributes to Neuronal Health in Postmenopausal Women With MS
Kathleen Fuchs, PhD
University of Virginia, Charlottesville, Virginia, USA
Oral estriol treatment is associated with a decrease in number and volume of gadolinium enhancing lesions on MRI. This suggests that estrogen products offer some degree of neuroprotection. To date, it has not been demonstrated if postmenopausal women with MS derive disease-modifying benefit of hormone replacement therapy (HRT).
Objectives: In a pilot study of postmenopausal women with MS, 1H MR Spectroscopy (MRS) was used to compare the level of N-acetylaspartate (NAA)—a putative marker of neuronal integrity—in women with and without HRT.
Methods: We evaluated 16 women with clinically stable MS—8 on HRT, 8 not on HRT.
Results: The groups were comparable in age (mean50.5 years, p0.07) and disability level as assessed by the MS Functional Composite (mean z0.08, p0.72).....
There was a significant difference (p0.015) in the NAA/Cr ratio between the women on HRT (1.910.39)and the women not on HRT (1.410.32).
When age, level of disability, and use of immunomodulatory therapy were used as covariates in the statistical analysis, the significant difference between the groups remained.
Conclusions: In this small sample, we demonstrated that use of exogenous estrogen may contribute to neuronal health as measured by MRS. These findings will need to be replicated in a larger sample to determine if the benefits of HRT outweigh the risks in this population.
"Estriol treatment also has the potential to be more potent in halting disability in MS, since estrogens have been shown in animal models to be not only anti-inflammatory, but also to directly reduce brain injury."
Users browsing this forum: No registered users